FDA

Crucial research by Neil Osheroff and his lab leads to approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name Blujepa, will be available starting later this year, potentially bringing relief to thousands of women who struggle with uncomplicated urinary tract infections. Read More

The chair of the U.S. Federal Communications Commission, Ajit Pai, recently visited Allen County Schools in Kentucky to see a demonstration of the new school-based telemedicine program. Read More

Ron Eavey, MD, Guy M. Maness Professor and chair of Otolaryngology and director of the Vanderbilt Bill Wilkerson Center, far right, testified recently at the Food and Drug Administration in Washington, D.C., along with members of Ear Community. Read More

Facilitated reporting of medication-related events in the intensive care unit can provide opportunities for optimizing quality of care and patient safety. Read More

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read More

Recent advances in robotics technology make it possible to create prosthetics that can duplicate the natural movement of human legs which promises to dramatically improve the mobility of lower-limb amputees. Read More

Vanderbilt is taking part in a national study to test in older adults the use of a vaccine designed to protect children against a common cause of pneumonia. Read More

A Vanderbilt study shows that a class of drugs used to treat autoimmune diseases does not increase the chance of hospitalization for serious infection. Read More

Attention Deficit Hyperactivity Disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta and Strattera between 1998 and 2005. Read More